

# POZEN<sup>®</sup>

INC.

The Pharmaceutical Development Company

**Corporate Headquarters:**  
1414 Raleigh Road, Suite 400  
Chapel Hill, North Carolina 27517  
Main: 919-913-1030 / Fax: 919-913-1039

**Contact:**  
Fran Barsky  
Director, IR  
919-913-1044

POZEN is a pharmaceutical company committed to developing therapeutic advancements for diseases with unmet medical needs where it can improve efficacy, safety, and/or patient convenience. With less than 40 employees, POZEN is focused in the pain area of innovative drug development and in creating strategic, high-value partnerships with larger pharmaceutical companies for the commercialization of the company's drug candidates.



## POZEN Product Pipeline Status

Product	Pre-clinical	Phase I	Phase II	Phase III	NDA	Market
Treximef™ (GSK) Migraine	→					
PN 400 (AZN) "Safer NSAID"	→					
PA 32540 "Safer Aspirin"	→			→		
PA 32520/50040 Possible Cancer Doses	→					
PA 08140 Use with NSAIDs	→					
Lornoxicam Inj – Acute Pain	→					

**Treximef™** (formerly known as Trexima™) using POZEN's MT 400™ technology, is being developed in collaboration with GlaxoSmithKline (GSK) as a novel combination of sumatriptan, formulated with GSK's RT technology, and naproxen sodium, in a single tablet for the acute treatment of migraine headaches. POZEN completed the Phase III trials and submitted the NDA in August 2005. The company received an Approvable letter from the FDA in June 2006. The FDA determined that *Treximef* is effective; however, the Agency has requested additional safety information. POZEN received a second Approvable Letter from the FDA in August 2007. The agency requested the company to address one pre-clinical study in which genotoxicity was seen for the combination of naproxen sodium and sumatriptan, but not with either component alone. The company submitted a response, which has been accepted by the FDA. The PDUFA date is April 15, 2008.

**PN 400** is being developed for the relief of the signs and symptoms associated with conditions such as osteoarthritis, rheumatoid arthritis and ankylosing spondylitis in patients who are at risk for developing NSAID-associated gastric ulcers. In August 2006, the company signed an exclusive global collaboration agreement with AstraZeneca for the co-development and commercialization of proprietary fixed dose combinations that provide the coordinated delivery of the NSAID, naproxen, with the proton pump inhibitor (PPI), esomeprazole magnesium, in a single tablet. PN 400 is designed to ensure adherence since the PPI is administered with every dose of NSAID. POZEN initiated the Phase III trials for PN 400 in September 2007.

**The PA product candidate** is being developed as a "safer aspirin" and combines aspirin with a PPI for cardiovascular protection along with the potential reduction in the risk of colorectal cancer and adenomas. Adenomas are precursors of most colorectal cancers and prevention of adenomas will most likely also prevent colorectal cancer, as reported in a March 2003 New England Journal of Medicine article. The PA product candidate is intended to provide fewer gastrointestinal side effects and complications compared to an NSAID or enteric coated aspirin taken alone. POZEN conducted a proof-of-concept study with its PA product candidate. Study results were positive.

### Common Stock Listing:

Ticker Symbol: POZN  
NASDAQ Stock Market

**Founded:** 1996      **IPO:** October 2000

**Employees:** 36

**Website:** [www.pozen.com](http://www.pozen.com)

### Executive Officers:

John R. Plachetka, Pharm.D.  
*Chairman, President & CEO*  
William L. Hodges, CPA  
*Sr. VP & Chief Financial Officer*  
Marshall E. Reese, Ph.D.  
*Exec. VP, Product Development*  
Gilda M. Thomas  
*Sr. VP & General Counsel*

### Analyst Coverage:

BMO Capital Markets - *Robert Hazlett*  
Citigroup Investment Research - *Lucy Lu*  
Cowen & Co. - *Ian Sanderson*  
Broadpoint Capital - *David Lickrish*  
Jefferies & Company, Inc. - *Eun Yang, Ph.D*  
Lazard Capital Markets - *Megan Murphy*  
Morgan Joseph - *Eugene Trogan*  
RBC Capital Markets - *Ken Trbovich, CFA*  
R.W. Baird - *Larry Neibor*  
Susquehanna Financial Group -  
*Angela Larson*  
Wachovia Securities Equity Research -  
*Michael Tong*  
Zacks Equity Research - *Jason Napodano*

### Upcoming Events:

**January 30<sup>th</sup>**  
Wachovia Securities Healthcare Conference

**March 4-5<sup>th</sup>**  
Susquehanna Healthcare Conference

### Recent News:

**January 15<sup>th</sup>**  
POZEN Submits Human Lymphocyte Study for  
*Treximef*

**November 28<sup>th</sup>**  
POZEN to Present at the RBC Capital Markets  
2007 Healthcare Conference

For further information, see  
[www.pozen.com](http://www.pozen.com)